Response of tumour cells to hypoxia: Role of p53 and NFkB

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 2, 1998, Pages 55-61

  Royds, J A ^a   Dower, S K ^a   Qwarnstrom, E E ^a   Lewis, C E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Angiogenesis; Hypoxia; NFkB; P53

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53;

CELL HYPOXIA; CELL SURVIVAL; CLONOGENESIS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION;

EID: 0031838786     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.2.55     Document Type: Review

References (50)

1. Vaupel PW. The influence of tumour blood flow and microenvironmental factors on the efficacy of radiation, drugs and localised hyperthermia. Klin Padiatr 1997;209:243-49.
2. Gimbione MA Jr, Leapman SB, Cotran RS, et al. Tumour domancy in vitro by prevention of neovascularization. J Exp Med 1972;136:261-76.
3. Jain R. Vascular and interstitial physiology of tumours: role in cancer detection and treatment. In: Lewis CE, Bicknell R, Ferrara N, eds. Tumour angiogenesis. Oxford: Oxford University Press, 1997;45-60.
4. Leek RD, Harris AL, Lewis CE. Cytokine netwoorks in solid human tumours: regulation of angiogenesis. J Leuk Biol 1994;56:423-35.
5. Brown LF. Expression of vascular permeability factor (VEGF) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
6. Zhang H-T, Craft P, Scott PAE, et al. Enhancement of tumour growth and vascular density by transfection of vascular endothelial growth factor into MCF7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:213-19.
7. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumour dissemination by a mechanism distinct from its effect on primary tumour growth. Cancer Res 1996;56:921-4.
8. Carmeliet P, Ferreir V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
9. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth-factor gene to human-chromosome 6P21.3. Circulation 1996;93:1493-5.
10. 1. Cancer Res 1996;56: 2161-6.
11. Long X, Boluyt MO, Hipolito MdeL, et al. P53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest 1997;99:2635-43.
12. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92: 5510-14.
13. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoetin gene in transgenic mice. Mol Cell Biol 1992; 12:5447-54.
14. Masatsugu E, Shinichiro T, Noboru Y, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor la regulates the VEGF expression and its potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-8.
15. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), atranscription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
16. Graeber TG, Peterson JF, Tsai M. Hypoxia induces the accumulation of p53 protein but the activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-77.
17. Kim CY, Tsai MH, Osmanian C, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low oxygen conditions. Cancer Res 1997;57: 4200-4.
18. Titsy T. A p53 mt provides a gain-of-function phenotype affecting cell cycle checkpoint control. Proceedings of the 8th international p53 workshop, Dundee, 1996.
19. Enholm B, Paavonen K, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997;14:2475-83.
20. Kuwabara K, Ogawa S, Matsumoto M, et al. Hypoxiamdiated induction of acidie/basic FGF and PDGF in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995;92:4606-10.
21. Damert A, Machein M, Breier G, et al. Upregulation of VEGF expression in a rat glioma is conferred by two distinet hypoxia-driven mechanisms. Cancer Res 1997;57: 3860-4.
22. Dameron KM, Volpert OV, Twainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thromhospondin 1. Science 1944;265:1582-4.
23. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human VEGF gene expression. Cancer Res 1995;55:6161-5.
24. Agani F, Kirsch DG, Friedman SL, et al. P53 does not repress hypoxia-induced transcription of the VEGF gene. Cancer Res 1997;57:4474-7.
25. Keiser A, Weich HA, Brandner G, et al. Mt p53 potentiates PKC induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-9.
26. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995;11: 763-70.
27. Webley KM, Royds JA. Effect of mutation and conformation on the function of the tumour suppressor gene p53 in colorectal cancer. J Pathol. [In press.]
28. Plate KH, Breir G, Weich HA, et al. VEGF and glioma angiogenesis. Int J Cancer 1994;59:520-9.
29. Van Meier EG, Polverini PJ, Chazin VR, et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994;8:171-6.
30. Fontanini G, Vignati S, Mussi A, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997;75:1295-301.
31. Royds JA, Lewis CE, Leek RD, et al. Association of p53 status with tumour angiogenesis, grade, necrosis and macrophage activity in invasive breast cancer [abstract]. J Pathol 1997;182:17A.
32. Koong AC, Chen KY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa through the phosphorylation of IKBa on tyrosine residues. Cancer Res 1994;54:1425-30.
33. Samaniego F, Markham PD, Gendelman R, et al. Inflammatory cytokines induce endothelial cells to produce and release bFGF and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 1997;158:1887-94.
34. Schmedtje JF, Ji YS, Liu W, et al. Hypoxia induces cyclooxygenase-2 via the NFkB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272: 601-8.
35. DiDonato J, Mercurio F, Rosette C, et al. Mapping of the inducible I-k-B phosphorylation sites that signal its ubiquination and degradation. Mol Cell Biol 1996;16:1295-54.
36. Imbert V, Rupee RA, Livolsi A, et al. Tyrosine phosphorylation of IkB activates NFkB without proteolytic degradation of IkB. Cell 1996;86:787-98.
37. Singh S, Darnay BG, Aggarwal BB, et al. Site-specific tyrosine phosphorylation of IkB negatively regulates its inducible phosphorylation and degradation. J Biol Client 1996;271:31049-54.
38. Isreal A. IkB all zipped up. Nature 1997;388:519-21.
39. Beauparlant P, Kwan I, Bitar R, et al. Disruption of I-Kappa-B-alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene 1994;9:3189-97.
40. Hwang S, Ding A. Macrophages derived from C3H/HEJ (LPS(D)) mice respond to bacterial lipopolysaccharide by activating NF-Kappa-B Cancer Biochem Biophys 1995;14: 265-72.
41. Wu H, Lozano G. NFkB activation of p53. J Biol Chem 1994;269:20067-74.
42. Sun X, Shimizu H, Yamamoto K-I. Identification of a novel p53 promoter element involved in genotoxic stressinducible p53 gene expression. Mol Cell Biol 1995;15: 4489-96.
43. Jung M, Zhang Y, Lee S, et al. Correction of radiation senstivity in ataxia telangiectasia cells by a truncated IkB-α. Science 1995;268:1619-21.
44. Tuck SP, Crawford L. Characterisation of the human p53 gene promoter. Mol Cell Biol 1989;9:2163-72.
45. Baldwin AS. The NFkB and IkB proteins: new discoveries and insights. Ann Rev Immunol 1996;14:649-83.
46. Koong AC, Chen KY, Mivechi NF, et al. Hypoxic activation of nuclear factor K B is mediated by a ras and raf signalling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res 1994;54:5273-9.
47. Mazure NM, Chen KY, Yeh P, et al. Oncogenic transformation and hypoxia synergistically act to modulate VEGF expression. Cancer Res 1996;56:3436-40.
48. Denko NC, Chen KY, Laderoute KR, et al. Protease inhibitor TPCK represses Ha-ras (Val-12) transformation and nuclear factor-kappa B activation. Int J Oncol 1997;10: 895-900.
49. Liu Z, Hsu H, Goeddel DV, et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NFkB activation prevents cell death. Cell 1996;87:565-76.
50. Wu GH, Havyuong L, Bellas RE, et al. Inhibition of NFkB/Rel induces apoptosis in murine B cells. EMBO J 1996;15: 4682-90.